Basit öğe kaydını göster

dc.contributor.authorAraman, Ahmet
dc.contributor.authorBroadley, Kenneth J.
dc.contributor.authorGumbleton, Mark
dc.contributor.authorJohn, Elinor
dc.contributor.authorOzsoy, Yildiz
dc.contributor.authorBirchall, James C.
dc.contributor.authorYildiz, Ayca
dc.date.accessioned2021-03-05T15:50:35Z
dc.date.available2021-03-05T15:50:35Z
dc.date.issued2012
dc.identifier.citationYildiz A., John E., Ozsoy Y., Araman A., Birchall J. C. , Broadley K. J. , Gumbleton M., "Inhaled extended-release microparticles of heparin elicit improved pulmonary pharmacodynamics against antigen-mediated airway hyper-reactivity and inflammation", JOURNAL OF CONTROLLED RELEASE, cilt.162, ss.456-463, 2012
dc.identifier.issn0168-3659
dc.identifier.otherav_bdc51323-8f6e-421d-9e31-e5f9564caf5a
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/126071
dc.identifier.urihttps://doi.org/10.1016/j.jconrel.2012.07.008
dc.description.abstractInhaled heparin appears to provide benefit in the management of airway hyper-reactivity and inflammation. The pharmacodynamics of inhaled heparin are however transient. Providing sustained heparin concentrations in the respiratory tract should provide for an extended duration of action. We examined the in-vivo efficacy of a nebulised controlled-release microparticle formulation of heparin in modifying antigen-induced airway hyper-reactivity (AHR) and lung inflammation. Heparin-loaded biodegradable poly (D, L-lactide-co-glycolide) microparticles were prepared by spray-drying. Aerosol properties for both nebulised heparin solution and heparin microparticles displayed characteristics consistent with heparin delivery to the respiratory tract. In vitro release assays showed heparin to be released from the microparticles over 8-12 h and for the heparin to remain functional. Temporal pharmacodynamic responses were studied in an ovalbumin-sensitised in vivo model exhibiting AHR and airway inflammation. Despite a reduced total dose of heparin deposited in the airways following nebulisation with heparin microparticles, this treatment led to a more sustained inhibitory effect upon AHR and airway inflammation than equivalent doses of nebulised heparin solution. The work supports extended-release heparin as an inhalation dosing strategy in experimental therapeutic applications aimed at improving the pharmacodynamics of heparin in the treatment of AHR and lung inflammation. (C) 2012 Elsevier B. V. All rights reserved.
dc.language.isoeng
dc.subjectSağlık Bilimleri
dc.subjectKimya
dc.subjectEczacılık
dc.subjectTemel Eczacılık Bilimleri
dc.subjectYaşam Bilimleri
dc.subjectBiyokimya
dc.subjectAlkoloidler
dc.subjectTemel Bilimler
dc.subjectKİMYA, MULTİDİSİPLİNER
dc.subjectTemel Bilimler (SCI)
dc.subjectFARMAKOLOJİ VE ECZACILIK
dc.subjectFarmakoloji ve Toksikoloji
dc.subjectYaşam Bilimleri (LIFE)
dc.titleInhaled extended-release microparticles of heparin elicit improved pulmonary pharmacodynamics against antigen-mediated airway hyper-reactivity and inflammation
dc.typeMakale
dc.relation.journalJOURNAL OF CONTROLLED RELEASE
dc.contributor.departmentCardiff University , ,
dc.identifier.volume162
dc.identifier.issue2
dc.identifier.startpage456
dc.identifier.endpage463
dc.contributor.firstauthorID12557


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster